If it was H&S, it is barely half formed. At this point there would be several possibilities chart wise. The bull flag is nearly fully formed, so probability is heavily 80%+ bull flag set for a breakout, probably over $2 before year end or latest first week of Jan.
Not sure if it's true, but I heard after 3 years post gene therapy you grow a second nose on your neck, only it's upside down and so you can't shower anymore, else you'll drown.
Should know soon who is buying.
Just wanted to bump to rub it in the faces of all the thumb downers. Lesson for you, analysis, not hoping dreaming will make you money.
Sentiment: Strong Buy
Simple because that is still a modest reduction in risk. Only severe outbreak patients will be interested. Mild outbreak patients (majority of HSV2 expression) will have no interest in this.
Stop wondering. Who the heck is going to buy this? No third world countries and in the U.S., really only the percent who suffer from massive outbreaks will care and only a fraction of those will actually be treated and another fraction of that group will actually see results. Read the PR again, maybe you'll grasp it then. Positive development? Yes. But commercial opportunity? modest.